CORT News and Press, Corcept Therapeutics Incorporated From 01/30/26

2026-01-30 09:19:35 ET More on Corcept Therapeutics Why Corcept Therapeutics' Relacorilant Fell Short And What It Means For The Company Corcept: Korlym Defies Generics As Relacorilant Hits An FDA CRL (Rating Upgrade) Corcept Therapeutics: Despite FDA Blind Side, Rela...

2026-01-22 13:04:54 ET Swayampakula Ramakanth from H.C. Wainwright issued a price target of $105.00 for CORT on 2026-01-22 17:41:46. The adjusted price target was set to $105.00. At the time of the announcement, CORT was trading at $41.47. The overall price target consen...

2026-01-22 08:38:24 ET More on Corcept Therapeutics Why Corcept Therapeutics' Relacorilant Fell Short And What It Means For The Company Corcept: Korlym Defies Generics As Relacorilant Hits An FDA CRL (Rating Upgrade) Corcept Therapeutics: Despite FDA Blind Side, Rela...

Data demonstrate a 35 percent reduction in the risk of death Both dual primary endpoints (progression-free and overall survival) were met, without the need for biomarker selection and without increased safety burden Relacorilant’s New Drug Application (NDA) is under review by the U...

The DJS Law Group announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT ) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on...

2026-01-14 14:33:14 ET More on The Health Care Select Sector SPDR® Fund ETF XLV Vs. BME: Total Return Or Income, Which Healthcare Strategy Wins? Where To Find Outperformance In 2026 My S&P 500 Prediction On Sector Outperformers And Laggards In 2026 N...

Boston, Massachusetts--(Newsfile Corp. - January 13, 2026) - Block & Leviton is investigating Corcept Therapeutics Inc. (NASDAQ: CORT) for potential securities law violations. Investors who have lost money in their Corcept Therapeutics investment should contact the firm to learn more about ...

2026-01-12 13:39:27 ET More on the markets Powell Under Attack The Bullish Trend Everyone Is Waiting For, But Nobody's Looking At DOJ Vs. Powell: We Have A Valuation Problem (And 2 Strategies For Now) Wall Street pushes higher despite Powell investigation ...

New York, New York--(Newsfile Corp. - January 12, 2026) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT) or certain of its officers and di...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT ) for violations of the securities laws. The ...